INSIGHTS ON DRUG DEVELOPMENT

• How Solid-State Characterization Shapes Drug Development

  Mark Benger, Site Director at Cambrex Edinburgh, on solid-state characterization as an insurance policy — front-loaded work that quietly determines whether a program survives the jump from kilos to tonnes.

• Working With Clients To Develop Manufacturing Processes

  Greg Buenger, Group Leader of Chemical Development at Cambrex Charles City, on what it actually looks like when R&D hands a process to the plant — chemists on the floor for the first batch, advising operators and troubleshooting in real time.

• Emerging Technologies In Reactor Design

  Jillian Sheeran, Associate Director of Engineering at Snapdragon Chemistry, on how automation, feedback control, and machine learning are changing reactor design — with real-time monitoring that lets a process run continuously while the data comes to you.

• How Do You Start Process Transfer For A New Client?

  Anmaris Torres, Process Engineering Team Leader, on why a process transfer starts with a conversation across departments to figure out how to cut cycle time before commercial production begins.

• Market Dynamics Related To The Development And Commercialization Of Peptides

  7/23/2026

  Matt Bio, CSO of Cambrex and President of Snapdragon Chemistry, on the capacity bottleneck behind peptide shortages — and why moving from solid-phase to liquid-phase synthesis unlocks reactors already sitting idle around the world.

• Cross-Site Work Within Cambrex's Network

  7/24/2026

  Matthew Zart, Group Leader of Analytical Development, on what happens when a method arrives from another site — inheriting Phase II work from High Point and getting it commercial-ready for the QC lab.

• How AI And Automation Are Impacting Process Development

  7/23/2026

  David Ford, Senior Director of Chemistry at Snapdragon Chemistry, on the mountain of data behind every process development program — and why AI's real promise is surfacing the right piece of it at the moment a team needs to decide.

• Approaching Process Validation During Tech Transfer To Commercial Manufacturing

  7/23/2026

  Matthew Schiesher, Head of R&D at Cambrex Charles City, on validating processes under the clock — and how running multiple sites in parallel shortens the path to launch when patients are waiting.

• How Biocatalysts Address Process Development Issues

  7/23/2026

  Antje Gupta, General Manager of Cambrex IEP in Wiesbaden, on where biocatalysis outperforms conventional chemistry — matching enzyme classes to target conversions and production volumes to find the more scalable, more economical route.